Departamento de Farmacología, Facultad de Medicina, Universidad de Valencia, Valencia, Spain.
FISABIO - Hospital Universitario Doctor Peset, Valencia, Spain.
J Pathol. 2021 Jul;254(3):216-228. doi: 10.1002/path.5678. Epub 2021 May 25.
Liver fibrosis (LF) occurs as a result of persistent liver injury and can be defined as a pathologic, chronic, wound-healing process in which functional parenchyma is progressively replaced by fibrotic tissue. As a phenomenon involved in the majority of chronic liver diseases, and therefore prevalent, it exerts a significant impact on public health. This impact becomes even more patent given the lack of a specific pharmacological therapy, with LF only being ameliorated or prevented through the use of agents that alleviate the underlying causes. Hepatic stellate cells (HSCs) are fundamental mediators of LF, which, activated in response to pro-fibrotic stimuli, transdifferentiate from a quiescent phenotype into myofibroblasts that deposit large amounts of fibrotic tissue and mediate pro-inflammatory effects. In recent years, much effort has been devoted to understanding the mechanisms through which HSCs are activated or inactivated. Using cell culture and/or different animal models, numerous studies have shown that autophagy is enhanced during the fibrogenic process and have provided specific evidence to pinpoint the fundamental role of autophagy in HSC activation. This effect involves - though may not be limited to - the autophagic degradation of lipid droplets. Several hepatoprotective agents have been shown to reverse the autophagic alteration present in LF, but clinical confirmation of these effects is pending. On the other hand, there is evidence that implicates autophagy in several anti-fibrotic mechanisms in HSCs that stimulate HSC cell cycle arrest and cell death or prevent the generation of pro-fibrotic mediators, including excess collagen accumulation. The objective of this review is to offer a comprehensive analysis of published evidence of the role of autophagy in HSC activation and to provide hints for possible therapeutic targets for the treatment and/or prevention of LF related to autophagy. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.
肝纤维化(LF)是由于持续的肝损伤引起的,可以定义为一种病理性的、慢性的、伤口愈合过程,其中功能性实质逐渐被纤维组织取代。作为大多数慢性肝病中涉及的现象,并且因此普遍存在,它对公共健康产生了重大影响。鉴于缺乏特定的药理学治疗方法,这种影响变得更加明显,只有通过使用减轻潜在原因的药物才能改善或预防 LF。肝星状细胞(HSCs)是 LF 的基本介质,HSCs 在受到促纤维化刺激后激活,从静止表型转分化为肌成纤维细胞,这些细胞会沉积大量纤维组织并介导促炎作用。近年来,人们致力于理解 HSCs 被激活或失活的机制。通过细胞培养和/或不同的动物模型,许多研究表明自噬在纤维化过程中增强,并提供了具体证据来确定自噬在 HSC 激活中的基本作用。这种作用涉及 - 尽管可能不限于 - 脂质滴的自噬降解。已经表明,几种肝保护剂可以逆转 LF 中存在的自噬改变,但这些作用的临床证实仍有待确定。另一方面,有证据表明自噬参与 HSCs 中的几种抗纤维化机制,这些机制刺激 HSC 细胞周期停滞和细胞死亡或防止促纤维化介质的产生,包括过量胶原的积累。本综述的目的是对自噬在 HSC 激活中的作用的已发表证据进行全面分析,并为自噬相关的 LF 的治疗和/或预防提供可能的治疗靶点的提示。